|
|
Expert Outlook: Nuvation Bio Through The Eyes Of 9 Analysts
|
|
|
|
HC Wainwright & Co. Maintains Buy on Nuvation Bio, Lowers Price Target to $17
|
|
|
|
Nuvation Bio Reports Strong Early Sales For Lung Cancer Drug, Sets Growth Plans For 2026
|
|
|
|
Nuvation Bio, Eisai Strike Licensing Deal For Taletrectinib For Treatment Of Non-Small Cell Lung Cancer
|
|
|
|
Nuvation Bio And Eisai Announce Exclusive License And Collaboration Agreement Expanding Long-Term Global Footprint Of Taletrectinib, Marketed As IBTROZI In U.S. And Japan
|
|